These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 21134556)

  • 21. Medullary Thyroid Carcinoma Associated with Germline RET
    Xu JY; Grubbs EG; Waguespack SG; Jimenez C; Gagel RF; Sosa JA; Sellin RV; Dadu R; Hu MI; Trotter CS; Jackson M; Rich TA; Hyde SM; Sherman SI; Cote GJ
    Thyroid; 2016 Dec; 26(12):1744-1751. PubMed ID: 27673361
    [TBL] [Abstract][Full Text] [Related]  

  • 22. RET Proto-oncogene Gene Mutation Is Related to Cervical Lymph Node Metastasis in Medullary Thyroid Carcinoma.
    Wang S; Wang B; Xie C; Ye D
    Endocr Pathol; 2019 Dec; 30(4):297-304. PubMed ID: 31494787
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnosis, treatment, and follow-up of medullary thyroid carcinoma: recommendations by the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism.
    Maia AL; Siqueira DR; Kulcsar MA; Tincani AJ; Mazeto GM; Maciel LM
    Arq Bras Endocrinol Metabol; 2014 Oct; 58(7):667-700. PubMed ID: 25372577
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antitumor capacity of a dominant-negative RET proto-oncogene mutant in a medullary thyroid carcinoma model.
    Drosten M; Stiewe T; Pützer BM
    Hum Gene Ther; 2003 Jul; 14(10):971-82. PubMed ID: 12869215
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Nationwide Study of Multiple Endocrine Neoplasia Type 2A in Norway: Predictive and Prognostic Factors for the Clinical Course of Medullary Thyroid Carcinoma.
    Opsahl EM; Brauckhoff M; Schlichting E; Helset K; Svartberg J; Brauckhoff K; Mæhle L; Engebretsen LF; Sigstad E; Grøholt KK; Akslen LA; Jørgensen LH; Varhaug JE; Bjøro T
    Thyroid; 2016 Sep; 26(9):1225-38. PubMed ID: 27400880
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fine-needle aspiration cytology for medullary thyroid carcinoma: a single institutional experience in Japan.
    Suzuki A; Hirokawa M; Takada N; Higuchi M; Ito A; Yamao N; Hayashi T; Kuma S; Miyauchi A
    Endocr J; 2017 Nov; 64(11):1099-1104. PubMed ID: 28883261
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Medullary thyroid cancer: a promising model for targeted therapy.
    Torino F; Paragliola RM; Barnabei A; Corsello SM
    Curr Mol Med; 2010 Oct; 10(7):608-25. PubMed ID: 20712590
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Salinomycin and its derivatives as potent RET transcriptional inhibitors for the treatment of medullary thyroid carcinoma.
    Alqahtani T; Kumarasamy VM; Huczyński A; Sun D
    Int J Oncol; 2020 Jan; 56(1):348-358. PubMed ID: 31746350
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib.
    Hong D; Ye L; Gagel R; Chintala L; El Naggar AK; Wright J; Kurzrock R
    Mol Cancer Ther; 2008 May; 7(5):1001-6. PubMed ID: 18445656
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting of RET oncogene by naphthalene diimide-mediated gene promoter G-quadruplex stabilization exerts anti-tumor activity in oncogene-addicted human medullary thyroid cancer.
    Lopergolo A; Perrone R; Tortoreto M; Doria F; Beretta GL; Zuco V; Freccero M; Borrello MG; Lanzi C; Richter SN; Zaffaroni N; Folini M
    Oncotarget; 2016 Aug; 7(31):49649-49663. PubMed ID: 27351133
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Challenging clinically unresponsive medullary thyroid cancer: Discovery and pharmacological activity of novel RET inhibitors.
    La Pietra V; Sartini S; Botta L; Antonelli A; Ferrari SM; Fallahi P; Moriconi A; Coviello V; Quattrini L; Ke YY; Hsing-Pang H; Da Settimo F; Novellino E; La Motta C; Marinelli L
    Eur J Med Chem; 2018 Apr; 150():491-505. PubMed ID: 29549836
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnosis of medullary thyroid carcinoma by calcitonin measurement in fine-needle aspiration biopsy specimens.
    Kudo T; Miyauchi A; Ito Y; Takamura Y; Amino N; Hirokawa M
    Thyroid; 2007 Jul; 17(7):635-8. PubMed ID: 17696833
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel combination of withaferin A and sorafenib shows synergistic efficacy against both papillary and anaplastic thyroid cancers.
    Cohen SM; Mukerji R; Timmermann BN; Samadi AK; Cohen MS
    Am J Surg; 2012 Dec; 204(6):895-900; discussion 900-1. PubMed ID: 23231932
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diversity of mutations in the RET proto-oncogene and its oncogenic mechanism in medullary thyroid cancer.
    Hedayati M; Zarif Yeganeh M; Sheikholeslami S; Afsari F
    Crit Rev Clin Lab Sci; 2016 Aug; 53(4):217-27. PubMed ID: 26678667
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Beyond RET: potential therapeutic approaches for advanced and metastatic medullary thyroid carcinoma.
    Santarpia L; Ye L; Gagel RF
    J Intern Med; 2009 Jul; 266(1):99-113. PubMed ID: 19522829
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The HIV protease inhibitor nelfinavir down-regulates RET signaling and induces apoptosis in medullary thyroid cancer cells.
    Kushchayeva Y; Jensen K; Recupero A; Costello J; Patel A; Klubo-Gwiezdzinska J; Boyle L; Burman K; Vasko V
    J Clin Endocrinol Metab; 2014 May; 99(5):E734-45. PubMed ID: 24483157
    [TBL] [Abstract][Full Text] [Related]  

  • 37. RET Kinase-Regulated MicroRNA-153-3p Improves Therapeutic Efficacy in Medullary Thyroid Carcinoma.
    Joo LJS; Weiss J; Gill AJ; Clifton-Bligh R; Brahmbhatt H; MacDiarmid JA; Gild ML; Robinson BG; Zhao JT; Sidhu SB
    Thyroid; 2019 Jun; 29(6):830-844. PubMed ID: 30929576
    [No Abstract]   [Full Text] [Related]  

  • 38. Clinical and pathological analysis of 19 cases of medullary thyroid carcinoma without an increase in calcitonin.
    Zhou Q; Yue S; Cheng Y; Jin J; Xu H
    Exp Toxicol Pathol; 2017 Oct; 69(8):575-579. PubMed ID: 28552629
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cabozantinib for the treatment of progressive metastatic medullary thyroid cancer.
    Krajewska J; Olczyk T; Jarzab B
    Expert Rev Clin Pharmacol; 2016; 9(1):69-79. PubMed ID: 26536165
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neoadjuvant selpercatinib for advanced medullary thyroid cancer.
    Jozaghi Y; Zafereo M; Williams MD; Gule-Monroe MK; Wang J; Grubbs EG; Vaporciyan A; Hu MI; Busaidy N; Dadu R; Waguespack SG; Subbiah V; Cabanillas M
    Head Neck; 2021 Jan; 43(1):E7-E12. PubMed ID: 33169506
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.